- Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions - http://eyedocnews.com -
EyeGate Pharma Announces That EGP-437 Improved Signs and Symptoms of Dry Eye Syndrome in a Phase II Study
Posted By Dr. Ari Weitzner On June 10, 2009 @ 11:05 am In Dry Eye | Comments Disabled
EyeGate Pharma announced last week that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, improved signs and symptoms in patients with dry eye syndrome (DES) in a Phase II study.
The Phase II single-center, randomized (105 patients), double-masked, placebo-controlled patient study evaluated the safety and efficacy of a corticosteroid solution (EGP-437) administered by the EyeGate® II Delivery System (at two dose levels) twice over a three-week period.
In the top-level analysis, investigators observed that EGP-437 significantly (p < 0.05) improved signs and symptoms of DES during the three-week environmental component, which included three CAE exposures and two doses. EGP-437 also improved signs and symptoms when studied as a treatment and preventative in conjunction with the CAE.
Read [1] the full release.
Article printed from Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions: http://eyedocnews.com
URL to article: http://eyedocnews.com/001294-eyegate-pharma-announces-that-egp-437-improved-signs-and-symptoms-of-dry-eye-syndrome-in-a-phase-ii-study/
URLs in this post:
[1] Read: http://www.eyegatepharma.com/pdf/news2009/EyeGate%20Dry%20Eye%20Results%2003%20June%2009%20FINAL.pdf
Click here to print.
Copyright © 2008 Eye Doc Talk. All rights reserved.